2017 TRI Factsheet: Chemical - 1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE, 004080313
Select 2017 National Analysis Dataset (released October 2018)
The Toxics Release Inventory (TRI) tracks the management of certain toxic chemicals that may pose a threat to human health and the environment. Certain industrial facilities in the U.S. must report annually how much of each chemical is recycled, combusted for energy recovery, treated for destruction, and disposed of or otherwise released on- and off-site. This information is collectively referred to as production-related waste managed.
|1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE ranks 305 out of 497 chemicals reported to TRI in 2017 (Rank 1 = highest releases)|
Under the Pollution Prevention Act of 1990, TRI collects information to track industry progress in reducing waste generation and moving towards safer waste management alternatives. EPA encourages facilities to first eliminate waste at its source (source reduction). For waste that is generated, the preferred management method is recycling, followed by energy recovery, treatment, and as a last resort, disposing of or otherwise releasing the waste. Learn more about Pollution Prevention and TRI.
Source Reduction: View Facilities Reporting Newly Implemented Activities for 1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE
The following charts represent releases of TRI-covered chemicals to the environment in the Chemical 1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE, 004080313. A "release" of a chemical means that it is emitted to the air or water, placed in some type of land disposal, or transferred off-site for disposal or release.
1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE, 004080313
1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE was added to the TRI list in 1995.
Learn more about 1-(3-CHLOROALLYL)-3,5,7-TRIAZA-1-AZONIAADAMANTANE CHLORIDE chemical uses, proprieties and other regulatory information.
Cardiovascular: Referring to the heart and blood vessels. Effects may include arrhythmia, changes in blood pressure, heart failure and/or disorders of the peripheral blood vessels.